NASDAQ
21.11.24
17:07 Uhr
0,630 US-Dollar
-0,012
-1,92 %
-1,92 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.11. | Athira exploring strategic alternatives after Alzheimer's failure | 1 | BioPharma Dive | ||
| 08.11. | Athira Pharma GAAP EPS of -$0.75 misses by $0.04 | 1 | Seeking Alpha | ||
| 07.11. | Athira Pharma, Inc.: Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates | 37 | GlobeNewswire (Europe) | BOTHELL, Wash., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and... ► Artikel lesen | |
| 07.11. | Athira Pharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.11. | Pre-market Movers: ESSA Pharma, Theriva Biologics, VS MEDIA, Lexicon Pharmaceuticals, Athira Pharma | 683 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.00 A.M. ET).In the Green Theriva Biologics, Inc. (TOVX) is up over 47% at $2.15.
VS... ► Artikel lesen | |
| 18.10. | Athira Pharma faces Nasdaq delisting over share price | 1 | Investing.com | ||
| 18.10. | Athira Pharma, Inc. - 8-K, Current Report | 8 | SEC Filings | ||
| ATHIRA PHARMA Aktie jetzt für 0€ handeln | |||||
| 26.09. | Athira Pharma stock plunges to 52-week low of $0.41 | 1 | Investing.com | ||
| 26.09. | Athira Pharma-Aktie stürzt auf 52-Wochen-Tief von 0,41 US-Dollar | 1 | Investing.com Deutsch | ||
| 20.09. | After Alzheimer's stumble, Athira lays off 70% of workforce and pivots to ALS small molecule | 2 | FierceBiotech | ||
| 19.09. | Athira Pharma stock faces pivot and workforce cuts amid trial setback - Mizuho | 1 | Investing.com | ||
| 18.09. | Athira Pharma-Aktie erreicht 52-Wochen-Tief bei 0,46 US-Dollar | 7 | Investing.com Deutsch | ||
| 17.09. | Athira Pharma, Inc.: Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases | 1 | GlobeNewswire (USA) | ||
| 17.09. | Athira Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.09. | Athira Pharma stock plunges to 52-week low of $0.46 | 1 | Investing.com | ||
| 06.09. | Athira Pharma executive sells shares on clinical trial milestone | 1 | Investing.com | ||
| 06.09. | Athira Pharma executive sells shares worth $1,429 | 1 | Investing.com | ||
| 06.09. | Athira Pharma CEO sells over $2.8k in company stock | 1 | Investing.com | ||
| 06.09. | Athira Pharma general counsel acquires shares, sells for $1.4k | 1 | Investing.com | ||
| 06.09. | Athira Pharma COO Rachel Lenington sells shares worth $1,429 | 1 | Investing.com |
Seite:
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,900 | -21,74 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| INFLARX | 1,868 | -3,96 % | InflaRx N.V.: InflaRx Receives Positive CHMP Opinion for GOHIBIC (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome | JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,384 | +3,78 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,000 | -0,83 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
| IOVANCE BIOTHERAPEUTICS | 7,602 | -1,66 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SAN CARLOS, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,146 | -2,07 % | Ocular Therapeutix Inc reports results for the quarter ended September 30 - Earnings Summary | ||
| COHERUS | 1,003 | -4,34 % | Coherus BioSciences, Inc.: Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update | - Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarter-over-quarter - - UDENYCA labeling and packaging production resuming at third-party contract manufacturing... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,685 | -5,88 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| BEAM THERAPEUTICS | 23,500 | -4,00 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| CHIMERIX | 0,847 | +1,07 % | Chimerix, Inc.: Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting | DURHAM, N.C., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 0,800 | -2,62 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY, in a Phase 1 Study in Patients with Solid Tumors | SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,945 | 0,00 % | Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2024 Earnings Call Transcript | ||
| ARDELYX | 4,732 | +1,26 % | ARDELYX, INC. - 8-K, Current Report | ||
| SPERO THERAPEUTICS | 1,150 | +0,52 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update | Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Nov.... ► Artikel lesen | |
| CIDARA THERAPEUTICS | 17,500 | +21,53 % | Cidara Therapeutics shares surge on $105M equity private placement |
ATHIRA PHARMA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,92 % bei einem Aktienkurs von 0,630 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ATHIRA PHARMA INC finden Sie auf Wallstreet Online.
